La Rosa Francesco, Dos Santos Silva Jonadab, Dereskewicz Emma, Invernizzi Azzurra, Cahan Noa, Galasso Julia, Garcia Nadia, Graney Robin, Levy Sarah, Verma Gaurav, Balchandani Priti, Reich Daniel S, Horton Megan, Greenspan Hayit, Sumowski James, Cuadra Merixtell Bach, Beck Erin S
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
medRxiv. 2024 Aug 11:2024.08.10.24311686. doi: 10.1101/2024.08.10.24311686.
Aging is associated with structural brain changes, cognitive decline, and neurodegenerative diseases. Brain age, an imaging biomarker sensitive to deviations from healthy aging, offers insights into structural aging variations and is a potential prognostic biomarker in neurodegenerative conditions. This study introduces BrainAgeNeXt, a novel convolutional neural network inspired by the MedNeXt framework, designed to predict brain age from T1-weighted magnetic resonance imaging (MRI) scans. BrainAgeNeXt was trained and validated on 11,574 MRI scans from 33 private and publicly available datasets of healthy volunteers, aged 5 to 95 years, imaged with 3T and 7T MRI. Performance was compared against three state-of-the-art brain age prediction methods. BrainAgeNeXt achieved a mean absolute error (MAE) of 2.78 ± 3.64 years, lower than the compared methods (MAE = 3.55, 3.59, and 4.16 years, respectively). We tested all methods also across different levels of image quality, and BrainAgeNeXt performed well even with motion artifacts and less common 7T MRI data. In three longitudinal multiple sclerosis (MS) cohorts (273 individuals), brain age was, on average, 4.21 ± 6.51 years greater than chronological age. Longitudinal analysis indicated that brain age increased by 1.15 years per chronological year in individuals with MS (95% CI = [1.05, 1.26]). Moreover, in early MS, individuals with worsening disability had a higher annual increase in brain age compared to those with stable clinical assessments (1.24 vs. 0.75, p < 0.01). These findings suggest that brain age is a promising prognostic biomarker for MS progression and potentially a valuable endpoint for clinical trials.
衰老与大脑结构变化、认知能力下降和神经退行性疾病相关。脑龄是一种对健康衰老偏差敏感的成像生物标志物,可洞察结构衰老变化,并且是神经退行性疾病中的一种潜在预后生物标志物。本研究介绍了BrainAgeNeXt,这是一种受MedNeXt框架启发的新型卷积神经网络,旨在根据T1加权磁共振成像(MRI)扫描预测脑龄。BrainAgeNeXt在来自33个健康志愿者的私有和公开可用数据集的11574次MRI扫描上进行了训练和验证,这些志愿者年龄在5至95岁之间,使用3T和7T MRI进行成像。将其性能与三种最先进的脑龄预测方法进行了比较。BrainAgeNeXt实现了2.78±3.64岁的平均绝对误差(MAE),低于比较方法(MAE分别为3.55、3.59和4.16岁)。我们还在不同图像质量水平上测试了所有方法,即使存在运动伪影和不太常见的7T MRI数据,BrainAgeNeXt也表现良好。在三个纵向多发性硬化症(MS)队列(273名个体)中,脑龄平均比实际年龄大4.21±6.51岁。纵向分析表明,MS患者的脑龄每年增加1.15岁(95%置信区间=[1.05, 1.26])。此外,在早期MS中,与临床评估稳定的个体相比,残疾恶化的个体脑龄的年增长率更高(1.24对0.75,p<0.01)。这些发现表明,脑龄是MS进展的一个有前景的预后生物标志物,并且可能是临床试验中有价值的终点指标。